This session allowed a reminder of the main deadlines for 2024, the year marked by the start of work on its mid-term assessment and the development of a second roadmap for the period 2026-2030. On this occasion, the National Cancer Institute presented to all stakeholders a proposal to evaluate the first roadmap (2021–2025), as well as the first timeline for the development of the second part of the ten-year strategy. Ministers returned to the landmark achievements presented in the 3rde report to the President of the Republic. They also called on all stakeholders to continue and intensify their efforts for the full success of the strategy for the benefit of the entire population.
2024: a crucial year for the interim report
The fight against cancer benefits from a long-term, 10-year strategy that provides transparency to stakeholders and drives deep transformation. Built around four priority areas, it aims to reduce the burden of disease in the daily lives of the French. With 237 activities allocated to a total budget of 1.74 billion euros, it receives funding in line with its ambitions within the first 5 years.
Its deployment, as provided for by Decree No. 2021-119 of February 4, 2021 (Art. L1415-2 1° Public Health Code), continues “in a dynamic manner.” Goals and priorities are adapted according to results through mid-term evaluation.
During a strategic steering committee meeting, the National Cancer Institute proposed an assessment methodology that will begin this year, less than two years after the end of the first roadmap. This aims to adjust themes and actions midway through strategy implementation. This includes identifying needs and levers for; where necessary, strengthen, adapt and complete the actions identified in the first roadmap, which expires in 2025.
This assessment work will:
For 237 actions:
- identify 237 actions that have been taken and possible follow-up actions;
- reformulate or refocus some of them;
- propose, if necessary, new actions.
For 41 topics:
- to measure the level of achievement of actions and, where possible, the achievement of expected results
For 4 priority axes:
- determine the main achievements and possible limits for achieving the goals.
This mid-term assessment, which will take place between mid-2024 and mid-2025, will be based on an assessment of the actions performed by each pilot, on the conclusion of the Institute’s International Scientific Council and on an analysis of the available key indicators.
All work done will be aimed at developing a second roadmap for 2026–2030.
2026–2030: second agreed roadmap with all participants and stakeholders
Following the completion of the mid-term assessment, work can begin on developing a second ten-year strategy roadmap for the period 2026–2030.
In addition to the evaluation, its development will be based on a review phase within the National Cancer Institute, a consultation phase with all partners and stakeholders, and a forward-looking review with all pilot projects. This will be the subject of regular exchange of information with the supervisory ministries.
National Cancer Institute leadership will also be consulted to provide input.
The year 2025 will be devoted in several stages to defining this second roadmap and its budgetary framework. The project will be subject to regular communication with the controlling ministries and will be brought to the attention of the governing bodies of the ten-year strategy and the National Cancer Institute.
The proposal for the second roadmap will be sent by the National Cancer Institute to the government at the end of 2025 for effective implementation in early 2026.
Interministerial Strategic Steering Committee
This inter-ministerial committee, chaired by the heads of the cabinets of the Ministers of Health and the Ministry of Higher Education, meets every year.
The body responsible for ensuring the smooth implementation of the strategy takes the necessary measures for strategic management, such as reorienting activities, adding or removing measures as recommended by the operational steering committee. Midway will consider the views of the National Cancer Institute’s scientific review board on the relevance of the 10-year cancer strategy.
It is composed of the directors of the central administration and the directors of the health agencies responsible for action, the director general representing the regional health agencies (ARS), the director general of the National Health Insurance Fund (CNAM), and the president and chief executive officer of the National Institute. Health and Medical Research (Inserm), President and CEO of the National Cancer Institute. It also includes two qualified individuals: Madame Linda CambonResearch Lecturer and Doctor of Public Health, Professor Pascal Hummelgastroenterologist and hepatologist.
Directions and goals of the 10-year cancer strategy
Axis 1 – “improving prevention”
- reduce the number of preventable cancers by 60,000 cases per year by 2040 (almost half of new cancer cases each year could be avoided);
- by 2025, conduct one million more screenings (breast, cervical and colorectal cancer screenings).
Axis 2 – limit consequences and improve quality of life.
- reduce by 2/3 to 1/3 the proportion of patients suffering sequelae 5 years after cancer diagnosis.
Axis 3 – fighting cancer with poor prognosis
- significantly improve survival of cancers with the worst prognosis by 2030 (cancers with a 5-year survival rate of less than 33%).
Axis 3 – ensuring progress benefits everyone
- ensure progress against cancer is accessible to all.
Resources
- Download 3e report on the ten-year strategy to the President of the Republic.
- View the 10-Year Cancer Strategy 2021-2030.
- Check out the 2021-2025 roadmap.
About the National Cancer Institute
The National Cancer Institute, an agency of public health and scientific expertise, was created by the Public Health Act of August 9, 2004. He is leading a national campaign to reduce the incidence and impact of cancer in our country. To achieve this, the institute brings together and coordinates the efforts of those involved in the fight against cancer in the areas of prevention, screening, care, research and innovation. Taking a comprehensive view of the medical, medical, scientific, social and economic aspects associated with cancer pathologies, it puts its actions at the service of all fellow citizens: patients, relatives, caregivers, users of the health care system, the population as a whole, and health care workers. , researchers and decision makers. The Institute ensures the implementation of the ten-year cancer control strategy for 2021-2030.
Related Posts
Experts say there are mental health barriers for black youth
“The economic benefits are potentially huge, but difficult to quantify today.”
